<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Omeros Corporation — News on 6ix</title>
<link>https://6ix.com/company/omeros-corporation</link>
<description>Latest news and press releases for Omeros Corporation on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 20 Apr 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/omeros-corporation" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835a67a78dffbe2df10b89e.webp</url>
<title>Omeros Corporation</title>
<link>https://6ix.com/company/omeros-corporation</link>
</image>
<item>
<title>Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer</title>
<link>https://6ix.com/company/omeros-corporation/news/sagimet-biosciences-announces-appointment-of-andreas-grauer-md-as-chief-medical-officer-1</link>
<guid isPermaLink="true">https://6ix.com/company/omeros-corporation/news/sagimet-biosciences-announces-appointment-of-andreas-grauer-md-as-chief-medical-officer-1</guid>
<pubDate>Mon, 20 Apr 2026 11:00:00 GMT</pubDate>
<description>SAN MATEO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced the appointment of Andreas Grauer, MD, as Chief Medical Officer, effective April 20, 2026. Sagimet’s prior Chief Medical Officer, Eduardo Bruno Martins, MD, DPhil, who will continue to support the Company as an external scientific advisor, has retired effecti</description>
</item>
<item>
<title>CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug)</title>
<link>https://6ix.com/company/omeros-corporation/news/cms-assigns-permanent-reimbursement-j-code-for-yartemlear-narsoplimab-wuug</link>
<guid isPermaLink="true">https://6ix.com/company/omeros-corporation/news/cms-assigns-permanent-reimbursement-j-code-for-yartemlear-narsoplimab-wuug</guid>
<pubDate>Thu, 16 Apr 2026 12:45:00 GMT</pubDate>
<description>SEATTLE, April 16, 2026--Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has assigned a permanent Healthcare Common Procedure Coding System (HCPCS) J-code for YARTEMLEA®. The J-code for YARTEMLEA (J1289) simplifies and streamlines billing and reimbursement for patients covered by U.S. government programs (e.g., Medicare) and commercial payers. The J-code will become effective July 1, 2026.</description>
</item>
<item>
<title>Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results</title>
<link>https://6ix.com/company/omeros-corporation/news/omeros-corporation-reports-fourth-quarter-and-year-end-2025-financial-results-3</link>
<guid isPermaLink="true">https://6ix.com/company/omeros-corporation/news/omeros-corporation-reports-fourth-quarter-and-year-end-2025-financial-results-3</guid>
<pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
<description>– Conference Call Today at 4:30 p.m. ET SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as</description>
</item>
<item>
<title>Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026</title>
<link>https://6ix.com/company/omeros-corporation/news/omeros-corporation-to-announce-fourth-quarter-and-full-year-2025-financial-results-on-march-31-2026</link>
<guid isPermaLink="true">https://6ix.com/company/omeros-corporation/news/omeros-corporation-to-announce-fourth-quarter-and-full-year-2025-financial-results-on-march-31-2026</guid>
<pubDate>Thu, 26 Mar 2026 12:45:00 GMT</pubDate>
<description>SEATTLE, March 26, 2026--Omeros Corporation (NASDAQ: OMER) today announced that it will issue its financial results for the fourth quarter and year ended December 31, 2025, on Tuesday, March 31, 2026 after market close. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss recent developments and highlights as well as the Company’s financial results.</description>
</item>
<item>
<title>Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment</title>
<link>https://6ix.com/company/omeros-corporation/news/omeros-announces-upcoming-presentation-at-ebmt-2026-highlighting-advances-in-ta-tma-treatment</link>
<guid isPermaLink="true">https://6ix.com/company/omeros-corporation/news/omeros-announces-upcoming-presentation-at-ebmt-2026-highlighting-advances-in-ta-tma-treatment</guid>
<pubDate>Sat, 21 Mar 2026 07:23:00 GMT</pubDate>
<description>SEATTLE, March 21, 2026--Omeros Corporation (NASDAQ: OMER) today announced that it will host an industry session at the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) on March 22, 2026, from 2:30pm - 4pm CET in Madrid, Spain. The session, titled "Advances in TA-TMA Treatment: Evaluating the Role of a Novel Targeted Therapy," will be co-chaired by Rafael Duarte, MD, PhD, Hospital Universitario Puerta de Hierro Majadahonda, and Mohamad Mohty, MD, PhD, Hôpit</description>
</item>
<item>
<title>Omeros Announces Successful Primate Study in OncotoX-AML™ Drug Program</title>
<link>https://6ix.com/company/omeros-corporation/news/omeros-announces-successful-primate-study-in-oncotox-amltm-drug-program</link>
<guid isPermaLink="true">https://6ix.com/company/omeros-corporation/news/omeros-announces-successful-primate-study-in-oncotox-amltm-drug-program</guid>
<pubDate>Tue, 17 Feb 2026 05:00:00 GMT</pubDate>
<description>— OncotoX-AML Effectively Ablated Myeloid Progenitor Cells that Give Rise to AML in Cancer Patients — SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (NASDAQ:</description>
</item>
<item>
<title>Omeros Announces First Commercial Sales of YARTEMLEA®</title>
<link>https://6ix.com/company/omeros-corporation/news/omeros-announces-first-commercial-sales-140000189</link>
<guid isPermaLink="true">https://6ix.com/company/omeros-corporation/news/omeros-announces-first-commercial-sales-140000189</guid>
<pubDate>Tue, 27 Jan 2026 14:00:00 GMT</pubDate>
<description>SEATTLE, January 27, 2026--Omeros Corporation (NASDAQ: OMER) today announced that the first commercial shipments of YARTEMLEA® (narsoplimab-wuug) to its distributors were completed last week, with orders from transplant centers beginning that same day. Both adult and pediatric patients with stem cell transplant-associated thrombotic microangiopathy (TA-TMA) are now receiving YARTEMLEA, including patients who have recently failed prior off-label C5-inhibitor regimens, in both hospital and outpati</description>
</item>
<item>
<title>Omeros Announces New Date for YARTEMLEA® Approval Conference Call</title>
<link>https://6ix.com/company/omeros-corporation/news/omeros-announces-date-yartemlea-approval-233600404</link>
<guid isPermaLink="true">https://6ix.com/company/omeros-corporation/news/omeros-announces-date-yartemlea-approval-233600404</guid>
<pubDate>Fri, 26 Dec 2025 23:36:00 GMT</pubDate>
<description>SEATTLE, December 26, 2025--Omeros Corporation (NASDAQ: OMER) today announced a revised date for its conference call to discuss the recent FDA approval of YARTEMLEA® (narsoplimab-wuug), the first and only therapy indicated for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).</description>
</item>
<item>
<title>FDA Approves Omeros’ YARTEMLEA® – First and Only Therapy Indicated for TA-TMA</title>
<link>https://6ix.com/company/omeros-corporation/news/fda-approves-omeros-yartemlea-first-140000875</link>
<guid isPermaLink="true">https://6ix.com/company/omeros-corporation/news/fda-approves-omeros-yartemlea-first-140000875</guid>
<pubDate>Wed, 24 Dec 2025 14:00:00 GMT</pubDate>
<description>SEATTLE, December 24, 2025--Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA® (narsoplimab-wuug) for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), an often-fatal complication of stem-cell transplantation driven by activation of the lectin pathway of complement. YARTEMLEA is the first and only approved lectin pathway inhibitor. YARTEMLEA selectively inhibits MASP-2, the e</description>
</item>
<item>
<title>Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros’ Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906)</title>
<link>https://6ix.com/company/omeros-corporation/news/omeros-corporation-announces-closing-asset-133000712</link>
<guid isPermaLink="true">https://6ix.com/company/omeros-corporation/news/omeros-corporation-announces-closing-asset-133000712</guid>
<pubDate>Mon, 01 Dec 2025 13:30:00 GMT</pubDate>
<description>SEATTLE, December 01, 2025--Omeros Corporation (Nasdaq: OMER) today announced the closing of the asset sale and licensing transaction between Omeros and Novo Nordisk for the candidate drug zaltenibart (formerly OMS906). Zaltenibart is a first-in-class, late-stage clinical humanized monoclonal antibody targeting MASP-3 – the most upstream and key activator of the alternative pathway of the complement system – and has shown multiple potential advantages over other alternative pathway inhibitors in</description>
</item>
<item>
<title>Omeros Corporation Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/omeros-corporation/news/omeros-corporation-reports-third-quarter-211100858</link>
<guid isPermaLink="true">https://6ix.com/company/omeros-corporation/news/omeros-corporation-reports-third-quarter-211100858</guid>
<pubDate>Thu, 13 Nov 2025 21:11:00 GMT</pubDate>
<description>SEATTLE, November 13, 2025--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2025, which include:</description>
</item>
<item>
<title>Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2025</title>
<link>https://6ix.com/company/omeros-corporation/news/omeros-corporation-announce-third-quarter-133000239</link>
<guid isPermaLink="true">https://6ix.com/company/omeros-corporation/news/omeros-corporation-announce-third-quarter-133000239</guid>
<pubDate>Tue, 11 Nov 2025 13:30:00 GMT</pubDate>
<description>SEATTLE, November 11, 2025--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended September 30, 2025, on Thursday, November 13, 2025, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights.</description>
</item>
<item>
<title>Omeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Treated with Narsoplimab Versus a Well-Matched External Control Group</title>
<link>https://6ix.com/company/omeros-corporation/news/omeros-announces-publication-highlighting-survival-123000888</link>
<guid isPermaLink="true">https://6ix.com/company/omeros-corporation/news/omeros-announces-publication-highlighting-survival-123000888</guid>
<pubDate>Thu, 16 Oct 2025 12:30:00 GMT</pubDate>
<description>SEATTLE, October 16, 2025--Omeros Corporation (Nasdaq: OMER) today announced the publication of a peer-reviewed manuscript in Blood Advances, a journal of the American Society of Hematology, detailing survival outcomes in adult patients with life-threatening transplant-associated thrombotic microangiopathy (TA-TMA) treated with narsoplimab across both the pivotal clinical trial and the global expanded access program (EAP). Narsoplimab inhibits MASP-2, the effector enzyme of the lectin pathway of</description>
</item>
<item>
<title>Novo Nordisk and Omeros announce asset purchase and license agreement for Omeros’ clinical-stage MASP-3 inhibitor zaltenibart (OMS906)</title>
<link>https://6ix.com/company/omeros-corporation/news/novo-nordisk-and-omeros-announce-asset-purchase-and-license-agreement-for-omeros-clinical-stage-masp-3-inhibitor-zaltenibart-oms906</link>
<guid isPermaLink="true">https://6ix.com/company/omeros-corporation/news/novo-nordisk-and-omeros-announce-asset-purchase-and-license-agreement-for-omeros-clinical-stage-masp-3-inhibitor-zaltenibart-oms906</guid>
<pubDate>Wed, 15 Oct 2025 12:30:00 GMT</pubDate>
<description>Zaltenibart has best-in-class potential across multiple rare blood and kidney disorders and will enhance Novo Nordisk’s Rare Disease portfolioOmeros is eligible to receive 340 million US dollars in upfront and near-term milestone payments, up to a total of 2.1 billion dollars including potential development and commercial milestones, plus tiered royalties on net sales Bagsværd, Denmark and Seattle, US, 15 October 2025 – Novo Nordisk and Omeros Corporation (Nasdaq: OMER) today announced that they</description>
</item>
<item>
<title>Omeros Announces Publication Highlighting Survival Outcomes in TA-TMA Patients Treated with Narsoplimab Under Its Global Expanded Access Program</title>
<link>https://6ix.com/company/omeros-corporation/news/omeros-announces-publication-highlighting-survival-124500834</link>
<guid isPermaLink="true">https://6ix.com/company/omeros-corporation/news/omeros-announces-publication-highlighting-survival-124500834</guid>
<pubDate>Tue, 02 Sep 2025 12:45:00 GMT</pubDate>
<description>SEATTLE, September 02, 2025--Omeros Corporation (Nasdaq: OMER) today announced the publication of a peer-reviewed manuscript in the American Journal of Hematology detailing survival outcomes in adult and pediatric patients with life-threatening transplant-associated thrombotic microangiopathy (TA-TMA) treated with narsoplimab through a global expanded access program (EAP). Narsoplimab inhibits MASP-2, the effector enzyme of the lectin pathway of complement, and is currently under review for mark</description>
</item>
<item>
<title>Omeros Corporation Reports Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/omeros-corporation/news/omeros-corporation-reports-second-quarter-200200627</link>
<guid isPermaLink="true">https://6ix.com/company/omeros-corporation/news/omeros-corporation-reports-second-quarter-200200627</guid>
<pubDate>Thu, 14 Aug 2025 20:02:00 GMT</pubDate>
<description>SEATTLE, August 14, 2025--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2025, which include:</description>
</item>
<item>
<title>Omeros Corporation to Announce Second Quarter Financial Results on August 14, 2025</title>
<link>https://6ix.com/company/omeros-corporation/news/omeros-corporation-announce-second-quarter-200200634</link>
<guid isPermaLink="true">https://6ix.com/company/omeros-corporation/news/omeros-corporation-announce-second-quarter-200200634</guid>
<pubDate>Mon, 11 Aug 2025 20:02:00 GMT</pubDate>
<description>SEATTLE, August 11, 2025--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended June 30, 2025, on Thursday, August 14, 2025, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights.</description>
</item>
<item>
<title>D. Boral Capital Acted as Exclusive Placement Agent to Omeros Corporation (Nasdaq: OMER) in Connection with its $22,000,000 Registered Direct Offering</title>
<link>https://6ix.com/company/omeros-corporation/news/d-boral-capital-acted-as-exclusive-placement-agent-to-omeros-corporation-nasdaq-omer-in-connection-with-its-dollar22000000-registered-direct-offering</link>
<guid isPermaLink="true">https://6ix.com/company/omeros-corporation/news/d-boral-capital-acted-as-exclusive-placement-agent-to-omeros-corporation-nasdaq-omer-in-connection-with-its-dollar22000000-registered-direct-offering</guid>
<pubDate>Thu, 31 Jul 2025 16:50:00 GMT</pubDate>
<description>NEW YORK CITY, NEW YORK / ACCESS Newswire / July 31, 2025 / On July 24, 2025, Omeros Corporation (Nasdaq:OMER) ("Omeros" or the "Company") entered into a securities purchase agreement with Polar Asset Management Partners to sell approximately $22,000,000 ...</description>
</item>
<item>
<title>Omeros Corporation Announces Pricing of $22 Million Registered Direct Offering</title>
<link>https://6ix.com/company/omeros-corporation/news/omeros-corporation-announces-pricing-22-120000222</link>
<guid isPermaLink="true">https://6ix.com/company/omeros-corporation/news/omeros-corporation-announces-pricing-22-120000222</guid>
<pubDate>Fri, 25 Jul 2025 12:00:00 GMT</pubDate>
<description>SEATTLE, July 25, 2025--Omeros Corporation (Nasdaq: OMER) ("Omeros" or the "Company") announced that on July 24, 2025 it entered into a securities purchase agreement with Polar Asset Management Partners to sell approximately $22 million of its common stock in a registered direct offering.</description>
</item>
<item>
<title>Omeros Submits Narsoplimab Marketing Authorization Application to the European Medicines Agency for the Treatment of TA-TMA</title>
<link>https://6ix.com/company/omeros-corporation/news/omeros-submits-narsoplimab-marketing-authorization-123000887</link>
<guid isPermaLink="true">https://6ix.com/company/omeros-corporation/news/omeros-submits-narsoplimab-marketing-authorization-123000887</guid>
<pubDate>Fri, 27 Jun 2025 12:30:00 GMT</pubDate>
<description>SEATTLE, June 27, 2025--Omeros Corporation (Nasdaq: OMER) today announced the recent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).</description>
</item>
</channel>
</rss>